ClinicalTrials.gg
TerminatedNCT07178704Updated Nov 13, 2026

The Metabolic and Genetic Drivers of Body Composition Changes Following Weight Loss Surgery

An observational study in Bariatric Surgery Patients, sponsored by The University of Texas Medical Branch, Galveston. Terminated at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by The University of Texas Medical Branch, Galveston · Observational

How we know

Why this study was terminated
poor accrual
Updated Nov 13, 2026Now TerminatedStudy documents posted+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
8
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Sarcopenia by The University of Texas Medical Branch, Galveston — none open to participants now, none under way, none of them phase 3. Sarcopenia · The University of Texas Medical Branch, Galveston.

Started
2025
the only one that year
Observational
3 of 10
none open now
Registered
10th of 10
by date

Among the 10 studies in Sarcopenia by The University of Texas Medical Branch, Galveston, this one is the only one that started in 2025, is one of 3 observational ones, and was the 10th registered.

Sarcopenia

1,334 studies on the registry are indexed under Sarcopenia; 418 are open to participants now.

Browse Sarcopenia studies →

Open to participants now

None of the 10 studies in Sarcopenia by The University of Texas Medical Branch, Galveston is open now. The open studies under Sarcopenia, anywhere →

Where they have run

Who these studies take

Of the 246 Sarcopenia studies recruiting now, 155 (63%) set no upper age limit and 32 (13%) stop at 75 or younger; 9 take children under 18; 62 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies in Sarcopenia by The University of Texas Medical Branch, Galveston as a file.
02

Study summary

Weight loss surgery is very good at reducing body weight but it can also cause the loss of both muscle and strength. Some patients undergoing weight loss surgery do not achieve their weight loss goals and regain the weight they lost. When this occurs, the loss of muscle and strength combined with the regain of weight can impact the individual's quality of life and ability to remain active and mobile.

The purpose of this study is to understand the behavioral, biological, and genetic factors that influence the success of weight loss surgery and its impact on muscle mass.

Bariatric surgery patients participating in the trial will be monitored prior to, and for a year following weight loss surgery, with data collected about their eating habits, hand grip strength, and the loss of fat, muscle, and body weight following surgery. In patients who undergo a routine endoscopy in advance of weight loss surgery a small sample of gut tissue will be collected to identify the expression (activity) of genes in their DNA.

03

Conditions studied

  • Bariatric Surgery Patients

Browse trials for

Keywords

  • Body composition
  • Sarcopenia
  • Weight loss surgery
  • Muscle function
  • Protein metabolism
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Patients will be recruited from those electing to undergo bariatric surgery at the University of Texas Medical Branch.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age: 18 to 65 years at time of consent
  • : 35-65 kg.m-2
  • Scheduled to undergo bariatric surgery at UTMB
  • All races and ethnic backgrounds
  • Ability to speak and read English
  • Subject has provided in a manner approved by the IRB and is willing and able to comply with the trial procedures.

Exclusion criteria

Exclusion Criteria (Bariatric Surgery Patients):

  • Fails the medical criteria for bariatric surgery.
  • Anemia (hematocrit \< 33 % or donated blood in the past 12 weeks.)
  • Recent (5 years or less) history of cancer
  • Systemic or use for 8 or more consecutive days in the past 6 months, or any use of anabolic steroids or growth hormones in the same period.
  • \< 35 or > 65 kg.m-2.
  • Acute infectious disease or chronic infection.
  • Pregnancy or breast-feeding.
  • Any medical condition that, in the opinion of the investigator, would place the subject at increased risk for participation.
  • History of prior non-compliance that would, in the opinion of the investigator, make it difficult for the subject to comply with the study procedures or follow the investigator's instructions.
  • Concurrent participation in another research study.
  • Use of an agent in the 30 days prior to signing .
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
8 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Bariatric Surgery Patients

    Patients due to undergo either sleeve gastrectomy or gastric bypass surgery.

06

What researchers measure

Primary outcomes

  1. Body composition

    Body composition will be determined in patients by whole-body bioelectrical impedance. Regional body composition will be additionally assessed in healthy volunteers and bariatric surgery patients undergoing metabolic assessment via whole-body dual-energy x-ray absorptiometry (DXA) imaging. Procedures will be performed on a single occasion in healthy volunteers and up to three times in bariatric patients undergoing metabolic assessment.

    Time frame: Measured at baseline in both healthy volunteers & bariatric surgery patients undergoing metabolic assessment. The latter will undergo repeat assessment on two further occasions across a 1 year period post surgery.

Secondary outcomes

  1. Dietary Protein Intake

    Dietary protein intake will be determined by participants completing three-day food diaries. This will be performed on a single occasion in healthy volunteers and up to three occasions in bariatric patients undergoing metabolic assessment.

    Time frame: Measured at baseline in both healthy volunteers & patients undergoing metabolic assessment. The latter will undergo repeat assessment on two further occasions across a 1 year period post surgery.

  2. Body weight

    Body weight will be determined using digital scales (in kg). Procedures will be performed on a single occasion in healthy volunteers and up to three times in bariatric patients.

    Time frame: Measured at baseline in both healthy volunteers & bariatric surgery patients. The latter will undergo repeat assessment on two further occasions across a 1 year period post surgery.

  3. Association between foregut gene expression and degree of weight reduction

    Assessed only in patients. Gene expression of the foregut will be analyzed in tissue collected from patients during the routine pre-operative upper endoscopy. Subsequently, participants will be stratified into those achieving: \<10%, 10-20%, or \>20% weight loss 12 months post-surgery, and differentially expressed genes between the three groups determined.

    Time frame: A single occasion from tissue collected during the routine pre-operative upper endoscopy. (baseline)

  4. Handgrip Strength

    Assessed using a handgrip dynamometer (in kg). Will be performed on a single occasion in healthy volunteers and up to three times in bariatric patients.

    Time frame: Measured at baseline in both healthy volunteers & bariatric surgery patients. The latter will undergo repeat assessment on two further occasions across a 1 year period post surgery.

  5. Energy Intake

    Energy intake assessed via the completion of a 3-day food diary. Will be performed on a single occasion in healthy volunteers and up to three times in bariatric patients undergoing metabolic assessment.

    Time frame: Measured at baseline in both healthy volunteers & bariatric surgery patients undergoing metabolic assessment. The latter will undergo repeat assessment on two further occasions across a 1 year period post surgery.

07

Study locations

1 site
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Given the small participant numbers involved, the sharing of individual participant data could carry the risk of re-identification of the study participants, despite the data being provided in de-identified form.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Nov 2025 to primary completion in Sep 2026, 10 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 13, 2026: primary completion Feb 2027 → Sep 2026 and completion Aug 2027 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2025
First posted
Sep 17, 2025
StartActual
Nov 4, 2025
Primary completionActual
Sep 29, 2026was Feb 2027
CompletionActual
Sep 29, 2026was Aug 2027
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Terminated poor accrual
changed Nov 13, 2026
Primary completion
Feb 2027→Sep 29, 2026 (actual)
Nov 13, 2026
Study completion
Aug 2027→Sep 29, 2026 (actual)
Nov 13, 2026
Enrollment
100 (estimated)→8 (actual)
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Recruiting→Terminated
    Why stopped poor accrual
    Primary completion Feb 2027→Sep 29, 2026 (now actual)
    Study completion Aug 2027→Sep 29, 2026 (now actual)
    Enrollment 100 (estimated)→8 (actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07178704
Responsible party
Sponsor
First posted
Sep 17, 2025
Start date
Nov 4, 2025
Primary completion
Sep 29, 2026
Completion
Sep 29, 2026
Last update
Nov 13, 2026

Study contacts

Emily J Lantz, PhD
principal investigator · The University of Texas Medical Branch

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion